Gene transfer of a soluble IL-1 type 2 receptor-Ig fusion protein improves cardiac allograft survival in rats. by Simeoni, E. et al.
www.elsevier.com/locate/ejcts
European Journal of Cardio-thoracic Surgery 31 (2007) 222—228Gene transfer of a soluble IL-1 type 2 receptor-Ig fusion protein
improves cardiac allograft survival in rats§
Eleonora Simeoni a,b,e,1, Jean Dudler c,e,1, Sylvain Fleury a,b,e, Jianping Li a,g,e,
Maria Pagnotta c,e, Manuel Pascual f,e, Ludwig K. von Segesser d,f,e, Giuseppe Vassalli a,e,*
aDepartment of Cardiology, University of Lausanne Medical School, Lausanne, Switzerland
bDepartment of Experimental Surgery, University of Lausanne Medical School, Lausanne, Switzerland
cDepartment of Rheumatology, University of Lausanne Medical School, Lausanne, Switzerland
dDepartment of Cardiovascular Surgery, University of Lausanne Medical School, Lausanne, Switzerland
eDepartment of Microbiology, University of Lausanne Medical School, Lausanne, Switzerland
fCenter for Organ Transplantation, University of Lausanne Medical School, Lausanne, Switzerland
gTransplant Laboratories, Novartis Pharma, Basel, Switzerland
Received 27 March 2006; received in revised form 11 October 2006; accepted 23 October 2006; Available online 19 December 2006AbstractObjective: Interleukin-1 (IL-1) mediates ischemia—reperfusion injury and graft inflammation after heart transplantation. IL-1 affects target
cells through two distinct types of transmembrane receptors, type-1 receptor (IL-1R1), which transduces the signal, and the non-signaling type-2
receptor (IL-1R2), which acts as a ligand sink that subtracts IL-1b from IL-1R1.We analyzed the efficacy of adenovirus (Ad)-mediated gene transfer
of a soluble IL-1R2-Ig fusion protein in delaying cardiac allograft rejection and the mechanisms underlying the protective effect. Methods: IL-1
inhibition by IL-1R2-Ig was tested using an in vitro functional assay whereby endothelial cells preincubated with AdIL-1R2-Ig or control virus were
stimulated with recombinant IL-1b or tumor necrosis factor-a (TNF-a), and urokinase-type plasminogen activator (u-PA) induction was measured
by zymography. AdIL-1R2-Ig was delivered to F344 rat donor hearts ex vivo, which were placed in the abdominal position in LEW hosts. Intragraft
inflammatory cell infiltrates and proinflammatory cytokine expression were analyzed by immunohistochemistry and real-time reverse
transcriptase-polymerase chain reaction (RT-PCR), respectively. Results: IL-1R2-Ig specifically inhibited IL-1b-induced u-PA responses in vitro.
IL-1R2-Ig gene transfer reduced intragraft monocytes/macrophages and CD4+ cell infiltrates ( p < 0.05), TNF-a and transforming growth factor-b
(TGF-b) expression ( p < 0.05), and prolonged graft survival (15.6  5.7 vs 10.3  2.5 days with control vector and 10.1  2.1 days with buffer
alone; p < 0.01). AdIL-1R2-Ig combined with a subtherapeutic regimen of cyclosporin A (CsA) was superior to CsA alone (19.4  3.0 vs 15.9  1.8
days; p < 0.05). Conclusions: Soluble IL-1 type-2 receptor gene transfer attenuates cardiac allograft rejection in a rat model. IL-1 inhibition may
be useful as an adjuvant therapy in heart transplantation.
# 2007 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved.
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Proinflammatory cytokines mediate ischemia—reperfu-
sion injury and stimulate immune responses leading to acute
graft rejection. Upregulation of a number of cytokines,
including interleukin-1 (IL-1), the prototypical and one of the
most potent early-acting inflammatory cytokines, occurs
very early after graft reperfusion [1] including in human heart
transplants [2,3]. Cytokine transcripts for IL-1a, IL-1b, and§ Presented as an abstract at The 24th Annual Meeting and Scientific Sessions
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doi:10.1016/j.ejcts.2006.10.042IL-2 increase with time after transplantation in cardiac
transplant recipients [3]. Acting in concert with tumor
necrosis factor-a (TNF-a), IL-1 upregulates adhesion mole-
cules on endothelial cells and leukocytes, thereby promoting
neutrophil adhesion [4]. E-selectin expression on arterioles is
upregulated between 3 and 6 h, followed by intercellular
adhesion molecule-1 (ICAM-1) that is upregulated on virtually
all endothelial cells by 6—12 h after heart transplantation
[5]. IL-1 promotes a destructive inflammation by activating
macrophages and T cells that release proinflammatory
cytokines, such as TNF-a and IL-8 [6,7]. Consequently, IL-1
is a central mediator of myocardial reperfusion injury and
early alloantigen-independent inflammatory events follow-
ing heart transplantation. This is manifested by the fact that
IL-1 can induce early failure of donor hearts placed in
syngeneic hosts [1,4]. In addition, IL-1 stimulates alloantigenurgery. Published by Elsevier B.V. All rights reserved.
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Therefore, IL-1 participates in both innate and allogeneic
immune responses to the graft.
IL-1 affects target cells through two distinct types of
transmembrane receptors that have a nearly identical
extracellular domain [6]. However, IL-1 type 1 receptor
(IL-1R1) has a 213-amino acid cytoplasmic domain that is
essential for signal transduction, whereas the type 2 receptor
(IL-1R2) has a shorter cytoplasmic domain and does not
transduce the signal. IL-1R1 is found mainly on T cells,
fibroblasts, keratinocytes, and hepatocytes, whereas IL-1R2
is found predominantly on B cells, macrophages, and
neutrophils. IL-1 activity is tightly regulated by multiple
mechanisms including the IL-1 receptor antagonist (IL-1Ra),
membrane IL-1R2, and circulating ‘soluble’ IL-1R1 and IL-1R2
extracellular domains [6]. Membrane IL-1R2 acts as a ‘decoy’
molecule, especially for IL-1b, thereby subtracting free IL-1b
released from inflammatory sites [9—11]. Cell surface IL-1R2
is the source of circulating ‘soluble’ IL-1R2 extracellular
domains that are released by proteolytic cleavage by a so far
unidentified metalloproteinase upon activation by second-
ary, IL-1-induced cytokines [12]. Soluble IL-1R2 is found in the
circulation in healthy subjects as well as in inflammatory
body fluids, such as synovial fluid [6]. Soluble IL-1R2
circulates in healthy humans at molar concentrations which
are 10-fold greater than those of IL-1b measured in patients
with sepsis and 100-fold greater than those observed after
intravenous IL-1b administration in patients with cancer
[13]. The rank of affinities for the two soluble receptors is
markedly different for the three IL-1 molecules. The rank for
the three ligands binding to soluble IL-1R1 is IL-1Ra > IL-
1a > IL-1b, whereas for IL-1R2, the rank is IL-1b > IL-
1a > IL-1Ra [6,7,14]. Soluble IL-1R2 binds IL-1b more avidly
than IL-1R1, but loses affinity for IL-1Ra [14]. This is an
attractive profile of ligand affinity for a candidate IL-1
inhibitor.
For this reason, we have constructed an adenoviral vector
expressing a soluble IL-1R2-Ig fusion protein. The vector’s
functional efficacy was confirmed using an in vitro IL-1
inhibition assay. In a rat heart transplantation model, IL-1R2-
Ig gene transfer into donor hearts mitigated allograft
rejection, resulting in prolonged graft survival.2. Materials and methods
2.1. Recombinant adenoviruses
The cDNA sequence coding for the extracellular portion of
IL-1R2 was cloned by RT-PCR from mouse 70Z3 B cell mRNA.
After confirmation by bi-directional sequencing, the cDNA
was subcloned in frame with an XbaI fragment encoding the
constant and hinge mIgG1 region (Fc-g fragment). The
resulting cDNA sequence encoding the IL-1R2-Ig fusion
protein was placed under the transcriptional control of a
CMV promoter into pC5 plasmid, yielding pC5-IL-1R2-Ig.
Adenoviral vectors were constructed using a novel method
based on direct DNA ligation [15]. Recombinant adenovirus
AdIL-1R2-Ig was generated by co-transfection of pC5-IL-1R2-
Ig with PacI-restricted DNA from AdP-EGFP, a D1-deleted
recombinant adenovirus that contains a unique PacI site, [15]onto 293 cells. Concentrated virus stock solutions were
prepared by two CsCl2 ultracentrifugation gradients and
stored in storage buffer (10 mmol/l Tris—HCl, pH 7.4,
1 mmol/l MgCl2, 10% glycerol). D1-deleted adenoviral
vectors containing no transgene (AdNull) or green fluorescent
protein (AdGFP) or LacZ (AdLacZ) reporter genes driven by a
CMV promoter were used as control or reporter vectors.
Transducing titers of viral stock solutions ranged from
6  1010 to 2  1011 plaque-forming units (PFU)/ml by plaque
titration assay (virus particles/PFU ratios 4—10).
2.2. Detection of IL-1R2-Ig expression in vitro
IL-1R2-Ig expression in HeLa cells preincubated with
either AdIL-1R2-Ig or control adenovector was detected by
Western blotting using both goat anti-mouse IgG (Fcg
fragment-specific) mAb (Jackson ImmunoResearch) and rat
anti-mouse IL-1R2 mAb (BD PharMingen) as primary anti-
bodies. In addition, IL-1R2-Ig expression was detected by flow
cytometry using R-PE-conjugated anti-mouse IL-1R2 mAb.
2.3. Detection of IL-1R2-Ig functional activity in vitro
An in vitro functional assay was used to demonstrate
specific IL-1 inhibition by IL-1R2-Ig. We took advantage of
the fact that human endothelial cells (HUVECs) produce and
release urokinase-type plasminogen activator (u-PA) upon
stimulation with cytokines, including human and mouse IL-
1b and TNF-a, and that they are easily transducible by
adenoviral vectors. HUVECs were preincubated with either
AdIL-1R2-Ig or control adenovirus for 24 h at amultiplicity of
infection (MOI) of 200. Subsequently, they were stimulated
with either recombinant mouse IL-1b or TNF-a at a
concentration of 10 ng/ml during 6 h. Induced u-PA activity
was measured by zymography in both cell extracts and
supernatants. Specific inhibition of IL-1 activity was
demonstrated as inhibition of the IL-1b, but not TNF-a-
induced increase in u-PA activity in cell extracts and
supernatants.
2.4. Gene transfer and heart transplantation
‘Principles of Laboratory animal care’ (NIH publication No.
86-23, revised 1985; http://grants1.nih.gov/grants/olaw/
references/phspol.htm) and institutional guidelines were
followed for animal experimentation. Male Fischer (F344)
and Lewis (LEW) rats (8—12 weeks old, purchased from IFFA
CREDO, L’Arbresle, France) were used as heart donors and
recipients, respectively. Gene transfer into the donor heart
was performed by intracoronary instillation of vector
containing solution immediately before transplantation.
First, 500 ml phosphate-buffered saline (PBS without Ca++/
Mg++; pH 7.4) was instilled slowly, in a retrograde manner,
into the aortic root. The syringe was then changed and 600 ml
virus (1010 PFU) containing solution was instilled slowly
(2—3 min) into the coronary arteries. Heterotopic cardiac
grafts were placed in the abdominal position of rats
anesthetized by isoflurane inhalation. Separate groups of
allograft recipients received a subtherapeutic regimen of
cyclosporin A (CsA; 1.5 mg/kg/day IM; days-1 to 3), either
alone or in conjunction with AdIL-1R2-Ig (1010 PFU). Graft
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Fig. 1. IL-1R2-Ig protein expression and functional activity in vitro. (A)
Western blot using anti-mIgG (Fcg fragment-specific) mAb. Left to right:
Purified mIgG1 (positive control); AdGFP-infected HeLa cells (MOI 80; ade-
noviral control); AdIL-1R2-Ig-infected HeLa cells (MOI 80); PBS (HeLa plus
control solution with no virus). Predicted IL-1R2-Ig size 80 kDa. Comparison
of Western blots under denaturing and nondenaturing conditions (data not
shown) demonstrated the predicted IL-1R2-Ig dimerization. (B) Flow cytome-
try using R-PE-conjugated anti-IL-1R2 mAb. IL-1R2-Ig expression is evidenced
as a rightward shift of the curve for AdIL-1R2-Ig (full line) versus the AdNull
control (dotted line). (C) Zymography for analysis of uPA activity in super-
natants and cell extracts of HUVECs pre-incubated with either AdIL-1R2-Ig or
AdGFP control vector (MOI200) 24 h before stimulation with 10 ng/ml mIL-1b
(6 h). AdIL-1R2-Ig prevents increases in uPA activity in response to IL-1b both in
supernatants and in cell extracts. uPA release also was stimulated by purified
TNF-a (data not shown), but it was not inhibited by preincubation with AdIL-
1R2-Ig (not shown).survival was monitored by daily abdominal palpation.
Rejection, defined as total cessation of heart beating, was
confirmed by direct graft examination.
2.5. Detection of IL-1R2-Ig expression in vivo
IL-1R2-Ig expression in vivo was determined by immuno-
histological staining of graft sections at 6 days, and by
Western blot analysis of graft tissue extracts and sera at 3 and
15 days after transplantation (n = 3 each). IL-1R2-Ig protein
expression was visualised by immunostaining using goat anti-
mouse IgG (Fcg fragment-specific) mAb, followed by biotin-
conjugated anti-goat IgG (Jackson Immuno Research Lab.),
StreptABComplex/HRP, and Nickel-DAB/H2O2 (Dako).
2.6. Immunohistology for inflammatory cells
Immunohistology was performed on cryostat sections of
hearts (n = 4/group) harvested on day 6 post-transplantation.
This time point was chosen for analysis because marked
inflammatory cell infiltrates are present (histological rejec-
tion), while massive infiltration and tissue destruction
(clinical rejection) have not occurred yet. Rats were
sacrificed by lethal pentobarbital injection, perfused with
ice-cold PBS, and cardiac grafts were immediately frozen in
OCT-compound. Four series of 8-mm cross-sections per heart
were cut at 500-mm steps perpendicular to the long axis from
the cardiac apex to the basis. Immunostaining of inflamma-
tory cells infiltrating the graft was performed with the
following primary mouse mAbs: anti-ED1-like (1C7; PharMin-
gen) that recognizes monocytes/macrophages; anti-T cell
receptor (TCR)ab (R73; PharMingen) that recognizes T
lymphocytes bearing T cell receptorab; anti-CD8a (OX-8;
PharMingen) that recognizes CD8a+ cells; and anti-CD4 (W3/
25; Accurate Chemicals) that recognizes CD4+ T lymphocytes
and macrophages; irrelevant mouse Ab (MOPC-31C; PharMin-
gen) was used as a control. Detection steps were biotin-
conjugated rabbit F(ab0)2 anti-mouse Ig (Jackson ImmunoR-
esearch), followed by StreptABComplex/HRP and DAB/H2O2
(Dako). Images were acquired using a Hyper-HAD-Axioscop
microscope and an Axiocam-MRcD system (Zeiss). Morpho-
metric analysis was performed in eight representative
microscopic fields (100) per heart section using the NIH-
Image-1.62 program, as described [16]. Inflammatory cell
infiltrates were expressed as myocardial surface areas
staining positive with the different immunohistochemical
markers normalized for the corresponding total myocardial
surface areas.
2.7. Quantitative RT-PCR
PBS-perfused hearts (n = 4/group) were excised on day 6
post-transplantation, and ventricular myocardial tissue
(300 mg) was placed in ice-cold PBS, cut into thin slices,
and submerged into RNAlater Stabilization Reagent. Total
RNAwas extracted using the Qiagen RNeasy midi kit. DNase-
treated RNA was utilized to generate cDNA by using the
reverse transcriptase Omniscript (Qiagen), random hex-
amer (Promega), and RNase inhibitor (Roche). cDNA
equivalent to 100 ng of total RNA was used for each PCR
reaction. Transcript levels for cytokines were measured byquantitative real-time PCR (Rotor-Gene 2000, Corbett
Research) using the SYBR-green dye. Hypoxanthine phos-
phoribosyltransferase (HPRT) was selected as an endogen-
ous control to correct for potential variation in RNA loading
or efficiency of the amplification reaction. Primer
sequences for rat cytokines were as follows: interferon-g
(IFN-g), 50-tcatggccctctctggctgttac-30 (sense) and 50-caa-
gaggaggctctttccttccatag-30 (antisense); interleukin-1b
(IL-1b), 50-cttcaaatctcacagcagcatctcg-30 (sense) and 50-
tccacgggcaagacataggtagc-30 (antisense); tumor necrosis
factor-a (TNF-a), 50-ctgtgcctcagcctcttctcattc-30 (sense)
and 50-ttgggaacttctcctccttgttgg-30 (antisense); transform-
ing growth factor-b (TGF-b), 50-ctaatggtggaccgcaacaacg-
30 (sense) and 50-tctggcactgcttcccgaatg-30 (antisense);
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Fig. 3. Survival curves of cardiac allografts receiving AdIL-1R2-Ig, AdNull, or
virus dilution solution alone (PBS; p < 0.01 for AdIL-1R2-Ig vs both AdNull and
PBS).RANTES, 50-ccatatggctgcgacaccactc-30 (sense) and 50-gcaca-
cacttggcggttcctt-30 (antisense); HPRT, 50-ctcatggactgattatg-
gacaggactg-30 (sense) and 50-cagcgctttaatgtaatccagcaggtc-30
(antisense). The threshold cycle (CT) was defined as the
fractional cycle number at which the reported fluorescence
reached a defined level. Target gene normalized to HPRT
expression is shown as DCT (=CT of target gene minus CT of
HPRT) [16].
2.8. Statistical analysis
Graft survival is shown as mean (SD) survival time and
Kaplan—Meier cumulative survival curves. Statistical analysis
of differences in graft survival between treated and control
groups was performed by product-limit (Kaplan—Meier)
survival estimates and Log-Rank test (JMP program, versionFig. 2. IL-1R2-Ig protein expression in vivo. (A) X-gal histochemical staining of
a transplanted heart section transducedwith AdLacZ. Myocardial areas expres-
sing the LacZ gene stain blue. (B) Immunohistochemical staining of a trans-
planted heart section transduced with AdIL-1R2-Ig, using anti-mIgG (Fcg
fragment-specific) mAb as the primary antibody (high magnification). (C)
Immunohistochemical staining for mIgG (Fcg fragment-specific); AdNull (con-
trol). (D) Western blot analysis of in vivo IL-1R2-Ig expression. Left to right:
Purified mIgG1 (positive control); supernatant of AdIL-1R2-Ig-infected cells in
vitro (positive control); rat serum, untransplanted (negative control); sera
from rats transplanted with AdIL-1R2-Ig-transduced grafts (samples: #22 and
#23; 3 days after transplantation). Same-size bands are present in the super-
natant of AdIL-1R2-Ig-infected cells and sera of heart-transplanted rats in the
AdIL-1R2-Ig group.5; SAS Institute). Immunohistological and RT-PCR data are
shown as median values (range). Statistical analysis of
differences in inflammatory cell infiltrates and cytokine
mRNA expression between treated and control groups was
performed by Mann—Whitney U-test. A p-value < 0.05 was
considered to be statistically significant.3. Results
3.1. IL-1R2-Ig protein expression and functional activity
in vitro
IL-1R2-Ig protein expression in vitro was demonstrated by
both Western blot (Fig. 1A) and flow cytometry in HeLa cells
preincubated with AdIL-1R2-Ig, but not in those preincubated
with control adenovector (Fig. 1B). IL-1 inhibitory activity of
HUVECs transduced with AdIL-1R2-Ig was evidenced by a
decrease in uPA activity in the supernatant in response to IL-
1b stimulation (Fig. 1C), indicating IL-1 inhibitory activity. IL-
1b-stimulated uPA release in HUVECs preincubated with
control adenovirus was not inhibited. TNF-a-stimulated uPA
release was unaffected in HUVECs preincubated with AdIL-
1R2-Ig (data not shown), indicating that IL-1R2-Ig specifically
inhibited IL-1b but not TNF-a.
3.2. Gene transfer efficiency and IL-1R2-Ig protein
expression in vivo
Perioperative and postoperative mortality was 1—2%
each; significant morbidity was not observed. Preliminary
studies aimed at establishing the method of gene transfer
were performed in cardiac isografts (LEW/LEW) using two
different doses of the AdLacZ reporter vector, 1010 and
109 PFU per heart. The higher virus dose appeared to bemore
efficient (Fig. 2A) and was used in subsequent experiments.
Cardiomyocytes were the predominant (>90%) cell type
expressing the transgene. Substantial numbers of b-gal-
positive cells were still detectable 40 days after transplanta-
tion, with a 2.5-fold decrease as compared with day 5 [17].
IL-1R2-Ig expression in cardiac allografts was detectable by
immunostaining at day 6 (Fig. 2B), and by Western blotting at
day 3 (data not shown; the protein band was faint). IL-1R2-Ig
was detectable in sera of rats transplanted with grafts
preincubated with AdIL-1R2-Ig at day 3 (Fig. 2D). Transgene
expression in grafts and sera was undetectable at day 15.
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Fig. 5. Real-time RT-PCR analysis of cytokine mRNA expression in cardiac
grafts. Data are shown as DCT (=CT of target gene minus CT of HPRT). Lower
values indicate higher mRNA expression. Horizontal bars are median values.3.3. IL-1R2-Ig gene transfer and graft survival
Allograft rejection was evaluated in the F344 to LEW
strain combination. Mean survival time (MST) of cardiac
allografts was comparable in hearts receiving AdNull (n = 8)
or virus dilution buffer alone (n = 9): 10.3  2.5 days and
10.1  2.1 days, respectively (Fig. 3). Survival of allografts
treated with AdIL-1R2-Ig (n = 10) was significantly prolonged
to 15.6  5.7 days ( p < 0.01 vs either control group). AdIL-
1R2-Ig combined with a subtherapeutic CsA regimen (n = 5;
one additional rat in this group died during surgery)
prolonged graft survival to 19.4  3.0 days, as compared
with 15.9  1.8 days for CyA alone (n = 8; p = 0.04). Cardiac
isografts (LEW/LEW) receiving virus dilution buffer alone
survived for >150 days.
3.4. Intragraft inflammatory cell infiltrates
Immunohistochemical analysis showed decreased intra-
graft inflammatory cell infiltrates 6 days after transplanta-
tion and IL-1R2-Ig gene transfer, as compared with the
AdNull group (Fig. 4). Specifically, CD4+ T lymphocytes
and macrophages infiltrating the graft were reduced by
60% ( p < 0.05) in the IL-1R2-Ig gene transfer group versus
controls. In addition, there were nonsignificant trends
toward decreases in the number of CD8+ cytotoxic T
lymphocytes and NK cell (by 40%), as well as in T
lymphocytes bearing the TCRab receptor (by 28%) in
the AdIL-1R2-Ig versus AdNull group. These results
reflect attenuated recruitment of CD4+ T cells and
monocytes/macrophages to grafts transduced with the
IL-1R2-Ig gene.Fig. 4. Immunohistological analysis of graft infiltration by inflammatory cells.
Upper panel: Photomicrographs of heart sections immunostained for the
indicated inflammatory cell markers. (A—D) AdNull; (E—H) AdIL-1R2-Ig. Lower
panel: Quantitative analysis of cell infiltrates staining positive for the indi-
cated inflammatory markers. Horizontal bars are median values.3.5. Intragraft cytokine mRNA expression
Real-time RT-PCR analysis showed decreased intragraft
cytokine transcripts for TNF-a and TGF-b ( p < 0.05).
Nonsignificant trends ( p = 0.083) toward decreased IL-1b
and RANTES mRNA expression were also observed in the AdIL-
1R2-Ig as compared with the AdNull group (Fig. 5). These
results suggest attenuated intragraft expression of these
cytokines after IL-1R2-Ig gene transfer.4. Discussion
IL-1a and-b are upregulated early after graft reperfusion
[1,4]. Here we show that expression and secretion of an IL-
1R2-Ig fusion protein potently and specifically blocks IL-1b
activities in vitro and attenuates acute cardiac allograft
rejection in a rat model in vivo. The beneficial effect of
localized IL-1R2-Ig expression in vivo was manifested by
decreased numbers of macrophages and CD4+ cells infiltrat-
ing the grafts, decreased intragraft TNF-a expression, and
prolonged allograft survival. IL-1R2-Ig gene transfer com-
bined with a subtherapeutic regimen of CsAwas modestly yet
significantly superior to CyA alone with respect to graft
survival, indicating an additive (but no synergistic) effect of
the two treatments in conjunction.
These findings are in good agreement with previous data
using different IL-1 inhibitors, such as recombinant IL-1Ra,
synthetic inhibitors, and neutralizing antibodies. Shiraishi
et al. [18] showed that recombinant IL-1Ra enhances CsA
immunosuppression and prolongs cardiac allograft survival in
the DA to BN rat model (MST: 8.2  0.7 days vs 5.3  1.4 days
in controls). Saadi et al. [19] reported that IL-1Ra reverses
expression of a set of genes that are upregulated in the early
steps of acute vascular rejection in a guinea pig-to-rat heart
xenotransplantation model, suggesting a central role for IL-1
in acute vascular rejection. Sano et al. [20] showed that
FR167653, a synthetic inhibitor of both IL-1 and TNF-a,
prolongs cardiac allograft survival in the BN to LEW rat model
(MST: 12.1  1.5 days vs 6.8  0.3 days in controls). Gerber
et al. [21] reported that microspheres containing both IL-1
and TNF-a neutralizing antibodies confer protection upon
mouse cardiac allografts. Finally, Suzuki et al. [22] reported
attenuated ischemia—reperfusion injury after IL-1Ra gene
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in allografts.
We have designed a novel IL-1 inhibitor that consists of a
soluble IL-1R2-Ig fusion protein. In nature, a competition
exists between the signaling IL-1 receptor, IL-1R1, and the
nonsignaling receptor, IL-1R2, for the same ligand. IL-1R2
binds IL-1b tightly, thus preventing binding to IL-1R1 and
receptor activation. Penton Rol et al. [23] showed that
exogenous expression of physiological numbers of surface IL-
1R2 molecules dampens IL-1 responses in myelomonocytic
cells in vitro. Soluble IL-1R2 binds and blocks processing of
the IL-1b precursor [14]. Physiologically, circulating soluble
IL-1R2 molecules contribute to the tight regulation of IL-1
cytokine cascades in humans, thereby preventing unneces-
sary or exaggerated activation of this potent proinflamma-
tory pathway. Our in vitro data indicate that overexpression
of a soluble IL-1R2-Ig fusion protein in human endothelial
cells selectively inhibits IL-1b-stimulated uPA induction.
In the transplantation model, IL-1R2-Ig expression in the
donor heart reduced the number of infiltrating macrophages,
CD4+ T cells and, to a lesser extent, CD8+ cells. Several
mechanisms could potentially account for these findings,
including decreases in IL-1-mediated endothelial cell activa-
tion, [6] in macrophage and Tcell stimulation, [6,7] as well as
in dendritic cell maturation [8]. Previous in vitro data
indicate that activation of endothelial cells by complement is
crucially dependent on IL-1a, leading to upregulation of IL-1a
and IL-1b [24]. As mentioned above, local overexpression of
IL-1Ra has been associated with cardioprotection from
ischemia—reperfusion injury [22]. In the present study, IL-
1R2-Ig gene transfer was associated with decreased intra-
graft cytokine transcripts for TNF-a and TGF-b as well as,
marginally, for IL-1b and RANTES. Downregulation of TNF-a
and IL-1b may be explained by inhibition of self-maintaining
feedback loops by which the two cytokines stimulate each
other’s production and secretion [6]. The RANTES chemokine
has been implicated in early migration and activation of
macrophages and CD45RO T lymphocytes in transplanted
hearts [25].
Transgene expression was short-lived in cardiac allografts,
presumably due to alloimmune responses leading to the
death of transgene-expressing cells (predominantly myo-
cytes). The intrinsically transient gene expression with
adenoviral vectors may have contributed to the rapid loss
of transgene expression; however, acute rejection appears to
be the primary cause for this, since we have observed
adenoviral LacZ expression over more than 40 days in cardiac
grafts placed in syngeneic recipients.
In this proof-of-principle study, an adenoviral vector was
employed to evaluate the efficacy of a novel IL-1 inhibitory
molecule in a heart transplantation model. Regarding future
clinical applications, gene therapy offers potential advan-
tages, such as local expression of the protective factor by the
graft itself, which reduces the risk of systemic effects.
Furthermore, gene therapy could obviate the need for daily
injections of a recombinant peptide, which would be
required due to the short half-lives of many peptides in
vivo, over extended periods of time. However, a number of
issues still need to be solved before gene therapy can be used
in clinical transplantation. Gene transfer protocols adapted
to the clinical setting, flawless vectors devoid of proin-flammatory effects, and reliable molecular systems that
permit to regulate transgene expression levels in vivo (‘gene
dosage’) are required.
Collectively, our findings indicate that IL-1R2-Ig gene
transfer mitigates acute rejection of cardiac allografts, even
though it ultimately fails to prevent it. Incomplete graft
protection might be due to methodological limitations, such
as suboptimal gene transfer efficiency and proinflammatory
effects of adenoviral vectors used in the present study.
Alternatively, they may be intrinsically related to the
functional redundancy of molecular cascades of proinflam-
matory cytokines, whereby blocking a single cytokine
pathway delays graft rejection, but ultimately fails to
prevent it. Because IL-1 inhibition interferes with early
alloantigen-independent immune responses in the context
of ischemia—reperfusion injury, which are not directly
targeted by current immunosuppressive agents, this approach
may be potentially useful as an adjunctive therapy in heart
transplantation.
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